Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tantum Verde 3 mg lozenges for pain relief in pediatric non-streptococcal pharyngotonsillitis
2025-521526-15-00Phase 4Authorised
- Sponsor
- Angelini Pharma
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of benzydamine in tonsillopharyngitis, sponsored by Angelini Pharma. Primary endpoints: Association between thermographic changes and baseline in pharyngotonsillar temperature over first 60 minutes and Association between pain score changes and baseline over first 60 minutes. Planned start Oct 2026; status: authorised.
02
Drugs
benzydamine
03
Conditions
tonsillopharyngitis
Beyond the preview
Go deeper on 2025-521526-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521526-15-00.